Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic User Fees Jump To Cover Inflation Increase, Backlog Fee Elimination

This article was originally published in The Pink Sheet Daily

Executive Summary

Manufacturers paying facility fees will shoulder most of the burden as GDUFA revenue is increased in FY 2014 for inflation and rebalanced to account for the loss of the backlog fee.

You may also be interested in...

Generic Facility Fees Are Smaller Part Of Funding Picture Than Expected

GDUFA revenue sometimes differed significantly from estimates even as collections remained strong, which may create momentum to change their structure.

Generic Drug User Fees Lower Than Expected, Thanks To Higher Volume

Fiscal year 2013 fees for new ANDAs, prior approval supplements, backlogged applications and drug master files are 3%-50% below the agency’s initial projections.

Generic User Fee Agreement Includes FDA Pledge To Determine Best Use Of Foreign Regulator Inspections

Draft commitment letter could be first step down globalization road in which FDA relies more on foreign governments to boost manufacturing oversight.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts